More articles from Interpreting Key Trials

  • Results of the Atlas Study
    Robert E. Hobbs, MD
    Cleveland Clinic Journal of Medicine November 1998, 65 (10) 539-542;

    A large clinical trial shows that high doses of an ACE inhibitor are superior to the low doses that many physicians prescribe.

  • The EPILOG Trial
    Matthew T. Roe, MD and David J. Moliterno, MD
    Cleveland Clinic Journal of Medicine May 1998, 65 (5) 267-272;

    The platelet glycoprotein Ilb/IIIa inhibitor abciximab, together with heparin in a low, weight-adjusted dose, markedly reduced the risk of acute ischemic complications during angioplasty, without increasing the risk of hemorrhage.

  • Angioplasty or fibrinolysis for acute MI?
    Sorin J. Brener, MD
    Cleveland Clinic Journal of Medicine February 1998, 65 (2) 75-81;

    Primary angioplasty is better than fibrinolytic therapy in acute myocardial infarction, but the advantage is not as large as we once thought.

  • Lipid-lowering therapy after coronary artery bypass surgery: the Post-CABG trial
    William J. Stewart, MD and Byron J. Hoogwerf, MD
    Cleveland Clinic Journal of Medicine July 1997, 64 (7) 347-351;

    The Post-CABG trial is an important milestone that demonstrates the benefits of treating hypercholesterolemia in patients who have had bypass surgery.

  • Digoxin’s effect on mortality and hospitalization in heart failure: implications of the DIG study
    Robert E. Hobbs, MD
    Cleveland Clinic Journal of Medicine May 1997, 64 (5) 234-237;

    Results of the world’s largest clinical trial resting the utility of digoxin in treating heart failure.

  • Lipid-lowering therapy for average lipid levels: The CARE trial
    Dennis L. Sprecher, MD
    Cleveland Clinic Journal of Medicine March 1997, 64 (3) 129-131;

    The CARE findings indicate that average LDL-cholesterol levels are too high in patients with coronary artery disease and can contribute to a reoccurrence of cardiovascular events.

  • The Bypass Angioplasty Revascularization Investigation (BARI) trial: implications for clinical practice
    Patrick L. Whitlow, MD
    Cleveland Clinic Journal of Medicine January 1997, 64 (1) 17-20;

    Both PTCA and CABG have their own inherent advantages and disadvantages, which must be weighed in the treatment decision for each patient.

  • Prevention of insulin-dependent diabetes mellitus: an overview of three trials
    Desmond A. Schatz, MD, Douglas G. Rogers, MD and Ben H. Brouhard, MD
    Cleveland Clinic Journal of Medicine September 1996, 63 (5) 270-274;

    Clinicians are eagerly awaiting the results of three large-scale trials using different approaches to prevent IDDM.

  • Therapy for acute ischemic stroke: the door opens
    Cathy A. Sila, MD and Anthony J. Furlan, MD
    Cleveland Clinic Journal of Medicine March 1996, 63 (2) 77-79;

    Finally, a successful trial of treatment for acute stroke. Now, a major effort is needed to reduce time from onset to treatment.

  • Cholesterol lowering: perspectives on the 4S and West of Scotland studies
    Jeffrey W. Olin, DO
    Cleveland Clinic Journal of Medicine March 1996, 63 (2) 80-83;

    Recent studies have resolved lingering doubts about cholesterol-lowering therapy, but questions on lipid management remain.

Pages